References
- Breast Cancer Chemotherapy Consensus Conference. JAMA. 1985; 254: 3461–3463
- Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1, 15, 71–85
- Hryniuk W, Levine M N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162–1170
- Norton L. Implication of kinetic heterogeneity in clinical oncology. Semin Oncol 1985; 12: 231–249
- Goldie J H, Coldman A J. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 1984; 44: 3643–3653
- Vogel C L, Smalley R V, Raney M, et al. Randomized trial of cyclophosphamide, doxorubicin, and 5-fIuorouracil alone or alternating with a “cycle active” non-cross resistant combination in women with visceral metastatic breast cancer: A Southeastern Cancer Study Group Project. J Clin Oncol 1984; 2: 643–651
- Tormey D C, Falkson G, Simon R M, et al. A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 1979; 2: 247–256
- Abeloff M D, Ettinger D S. Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy. Cancer Treat Rep 1977; 61: 1685–1689
- Ahmann D L, O'Fallon J, O'Connel M J, et al. Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Cancer Clin Trials 1978; 1: 219–226
- Nemoto T, Horton J, Simon R, et al. Comparison of four-combination chemotherapy programs in metastatic breast cancer: Comparison of multiple drug therapy with Cytoxan, 5-FU and prednisone, versus Cytoxan and adriamycin versus Cytoxan, 5-FU and adriamycin versus Cytoxan, 5-FU and prednisone alternating with Cytoxan and adrimaycin. Cancer 1982; 49: 1988–1993
- Kaplan E R, Meier P. Non parametric estimation from incomplete observation. J Am Statist Assoc 1958; 53: 457–481
- Lee E T. Statistical Methods for Survival Data Analysis, C A Belmont. Like Time Learning Publications. 1980
- Bonadonna G, Valagussa P, Rossi A, et al. Ten-year experience with CMF based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985; 5: 95–115
- Clavel M, Catimel G. Breast cancer. Chemotherapy in the treatment of advanced disease. Eur J Cancer 1993; 29A: 598–604
- Brambilla C, De Lena M, Rossi A, et al. Response and survival in advanced breast cancer after two non-cross resistant combinations. Br Med J 1976; l: 801–804
- Lebmann O A, Santos R L, Francheri Wilson C, et al. Mitomycin C and vindeesine in chemotherapy-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 1988; 7: 29, abstract
- Millward M J, Hendrick A, Cantwell B M. Fixed dose short course mitomycin-C with vincristine in advanced pretreated breast cancer. Ann Oncol 1990; 1: 373–374
- Hupperets P S, Fickers M M, Schouten L J, et al. A phase II study with mitomycin and vindesine in metastic pretreated breast cancer. Eur J Cancer 1991; 27: 520–521
- Day R. Treatment sequencing asymmetry and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876–3885